title: Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
abstract: Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.
authors.affiliation: Department of Neurobiology, University of Chicago, Chicago, IL 60637, USA.
authors.forename: Karthikeyan
authors.initials: K
authors.lastname: Veeraraghavalu
authors.forename: Can
authors.initials: C
authors.lastname: Zhang
authors.forename: Sean
authors.initials: S
authors.lastname: Miller
authors.forename: Jasmin K
authors.initials: JK
authors.lastname: Hefendehl
authors.forename: Tharinda W
authors.initials: TW
authors.lastname: Rajapaksha
authors.forename: Jason
authors.initials: J
authors.lastname: Ulrich
authors.forename: Mathias
authors.initials: M
authors.lastname: Jucker
authors.forename: David M
authors.initials: DM
authors.lastname: Holtzman
authors.forename: Rudolph E
authors.initials: RE
authors.lastname: Tanzi
authors.forename: Robert
authors.initials: R
authors.lastname: Vassar
authors.forename: Sangram S
authors.initials: SS
authors.lastname: Sisodia
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D008297:Male; D013764:Tetrahydronaphthalenes / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D013764:Tetrahydronaphthalenes